BHC(SH:600721) Sou Hu Cai Jing·2025-07-29 11:04Group 1 - The core viewpoint of the news is that Baihua Pharmaceutical (600721) has shown a positive stock performance with a closing price of 8.3 yuan, reflecting a 2.34% increase as of July 29, 2025 [1] - The trading volume was 347,900 hands with a transaction amount of 287 million yuan, indicating active market participation [1] - The net inflow of main funds was 30.28 million yuan, accounting for 10.53% of the transaction amount, with significant contributions from large orders [1] Group 2 - Baihua Pharmaceutical reported total operating revenue of 96.92 million yuan for the first quarter of 2025, representing a year-on-year growth of 6.65% [1] - The net profit attributable to shareholders was 20.72 million yuan, showing a slight increase of 0.28% year-on-year, while the non-recurring net profit decreased by 0.58% to 20.07 million yuan [1] - The company's liquidity ratios are strong, with a current ratio of 1.979 and a quick ratio of 1.624, alongside a debt-to-asset ratio of 30.45% [1] Group 3 - Xinjiang Baihua Village Pharmaceutical Group Co., Ltd. was established in 1996 and primarily engages in wholesale activities [2] - The company has made investments in 12 enterprises and participated in 16 bidding projects, indicating a proactive approach in business expansion [2] - Baihua Pharmaceutical holds 16 trademark registrations and has obtained 6 administrative licenses, showcasing its commitment to intellectual property and regulatory compliance [2]